Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melphalan vs BUCY+VP-16 Conditioning for Multiple Myeloma
NCT03385096Phase 3Unknown
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Jan 2018
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of busulfan, cyclophosphamide, etoposide in multiple myeloma (MM), sponsored by Nanfang Hospital, Southern Medical University. Status: unknown.
02
Drugs
busulfancyclophosphamideetoposide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03385096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03385096.